Related Experiment Videos
[Megaloblastic pancytopenia in a female patient with rheumatoid arthritis given methotrexate and amidopyrine
Abstract:
The paper is concerned with the development of megaloblastic pancytopenia in a female patient with grave rheumatoid arthritis. The patient had been given methotrexate (15 mg per week) for a long time, supplemented by amidopyrine (1.0 to 1.5 g/day). The author holds that the development of the above-indicated complication is provoked by both drugs interference into folate metabolism. It is concluded that caution should be taken as to the combined use of methotrexate with non-narcotic analgesic drugs, nonsteroidal anti-inflammatory agents and sulfanilamides.
Insights
Long-term use of methotrexate and amidopyrine can cause megaloblastic pancytopenia due to folate metabolism interference. Caution is advised when combining methotrexate with analgesics, anti-inflammatory drugs, or sulfanilamides.
Area of Science:
- Rheumatology
- Hematology
- Clinical Pharmacology
Background:
- Rheumatoid arthritis is a chronic autoimmune disease requiring long-term medication.
- Methotrexate is a common disease-modifying antirheumatic drug (DMARD).
- Drug-induced complications can arise from long-term polypharmacy.